非酒精性脂肪性肝病与非酒精性脂肪性肝炎的遗传学与表观遗传学:临床影响
非酒精性脂肪性肝病(NAFLD)是全球最常见的肝病,疾病进展存在显著个体差异,环境与多基因易感背景的交互决定表型。本综述讨论NAFLD进展的重要遗传与表观遗传修饰因素,并探讨将遗传数据转化为新药设计、诊断/预后生物标志物及个性化医疗的潜力与挑战。
要点
- NAFLD是复杂疾病性状,环境与多基因易感背景交互决定疾病表型并影响进展。
- I148M PNPLA3变异是NAFLD的主要常见遗传决定因素。
- TM6SF2、MBOAT7和GCKR的中等效应变异也对NAFLD有显著贡献。
核心结论
- NAFLD是复杂疾病性状,环境与多基因易感背景交互决定疾病表型并影响进展。
- I148M PNPLA3变异是NAFLD的主要常见遗传决定因素。
- TM6SF2、MBOAT7和GCKR的中等效应变异对NAFLD有显著贡献。
研究设计与样本
- 本综述讨论NAFLD进展的重要遗传与表观遗传修饰因素的研究现状。
主要发现
- NAFLD涵盖从单纯性脂肪变性、非酒精性脂肪性肝炎到纤维化、肝硬化和肝细胞癌的广泛疾病谱。
- NAFLD的标志是疾病进展存在显著的个体间差异。
- 多项全基因组关联研究和大型候选基因研究丰富了我们对NAFLD遗传基础的理解。
- I148M PNPLA3变异被确定为NAFLD的主要常见遗传决定因素。
- TM6SF2、MBOAT7和GCKR的中等效应变异也被证明有显著贡献。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis, through non-alcoholic steatohepatitis, to fibrosis and ultimately cirrhosis and hepatocellular carcinoma. A hallmark of NAFLD is the substantial inter-patient variation in disease progression. NAFLD is considered a complex disease trait such that interactions between the environment and a susceptible polygenic host background determine disease phenotype and influence progression. Recent years have witnessed multiple genome-wide association and large candidate gene studies, which have enriched our understanding of the genetic basis of NAFLD. Notably, the I148M PNPLA3 variant has been identified as the major common genetic determinant of NAFLD. Variants with moderate effect size in TM6SF2, MBOAT7 and GCKR have also been shown to have a significant contribution. The premise for this review is to discuss the status of research into important genetic and epigenetic modifiers of NAFLD progression. The potential to translate the accumulating wealth of genetic data into the design of novel therapeutics and the clinical implementation of diagnostic/prognostic biomarkers will be explored. Finally, personalised medicine and the opportunities for future research and challenges in the immediate post genetics era will be illustrated and discussed.
引用
- Eslam M, Valenti L, Romeo S, et al. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017. PMID: 29122391. doi:10.1016/j.jhep.2017.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。